» Articles » PMID: 36332927

Mer-tyrosine Kinase: a Novel Susceptibility Gene for SLE Related End-stage Renal Disease

Abstract

Objective: Lupus nephritis (LN) is a common and severe manifestation of SLE. The genetic risk for nephritis and progression to end-stage renal disease (ESRD) in patients with LN remains unclear. Herein, we aimed to identify novel genetic associations with LN, focusing on subphenotypes and ESRD.

Methods: We analysed genomic data on 958 patients with SLE (discovery cohort: LN=338) with targeted sequencing data from 1832 immunological pathway genes. We used an independent multiethnic cohort comprising 1226 patients with SLE (LN=603) as a replication dataset. Detailed functional annotation and functional epigenomic enrichment analyses were applied to predict functional effects of the candidate variants.

Results: A genetic variant (rs56097910) within the gene was associated with ESRD in both cohorts, meta-analysis OR=5.4 (2.8 to 10.6); p=1.0×10. We observed decreased methylation levels in peripheral blood cells from SLE patients with ESRD, compared with patients without renal SLE (p=2.7×10), at one CpG site (cg16333401) in close vicinity to the transcription start site of and located in a DNAse hypersensitivity region in T and B cells. Rs56097910 is linked to altered expression in kidney tissue in public eQTL databases. Two loci were replicated for association with proliferative LN: (rs6924535, p=1.6×10, OR=0.58) and () (rs942960, p=1.2×10, OR=2.64).

Conclusion: We identified a novel genetic risk locus, , associated with SLE-ESRD using the data from two large SLE cohorts. Through DNA methylation analysis and functional annotation, we showed that the risk could be mediated through regulation of gene expression. Our results suggest that variants in the gene are important for the risk of developing SLE-ESRD and suggest a role for and in proliferative LN.

Citing Articles

Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?.

Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska M, Tulchinsky E Cell Death Dis. 2025; 16(1):155.

PMID: 40044635 PMC: 11883011. DOI: 10.1038/s41419-025-07480-9.


Lupus Nephritis from Pathogenesis to New Therapies: An Update.

Roveta A, Parodi E, Brezzi B, Tunesi F, Zanetti V, Merlotti G Int J Mol Sci. 2024; 25(16).

PMID: 39201667 PMC: 11354900. DOI: 10.3390/ijms25168981.


Efferocytosis by macrophages in physiological and pathological conditions: regulatory pathways and molecular mechanisms.

Sheng Y, Hu W, Chen S, Zhu X Front Immunol. 2024; 15:1275203.

PMID: 38779685 PMC: 11109379. DOI: 10.3389/fimmu.2024.1275203.


Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.


B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus.

Hedenstedt A, Reid S, Sayadi A, Eloranta M, Skoglund E, Bolin K Lupus Sci Med. 2023; 10(2).

PMID: 37844960 PMC: 10582984. DOI: 10.1136/lupus-2023-000926.

References
1.
Westra H, Peters M, Esko T, Yaghootkar H, Schurmann C, Kettunen J . Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013; 45(10):1238-1243. PMC: 3991562. DOI: 10.1038/ng.2756. View

2.
Hanly J, OKeeffe A, Su L, Urowitz M, Romero-Diaz J, Gordon C . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2015; 55(2):252-62. PMC: 4939728. DOI: 10.1093/rheumatology/kev311. View

3.
Zeggini E, Scott L, Saxena R, Voight B, Marchini J, Hu T . Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40(5):638-45. PMC: 2672416. DOI: 10.1038/ng.120. View

4.
Ward L, Kellis M . HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011; 40(Database issue):D930-4. PMC: 3245002. DOI: 10.1093/nar/gkr917. View

5.
Parodis I, Ding H, Zickert A, Cosson G, Fathima M, Gronwall C . Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. PLoS One. 2019; 14(2):e0212068. PMC: 6370217. DOI: 10.1371/journal.pone.0212068. View